Subject Index

Abdominal compartment syndrome, severe acute pancreatitis and polymethacrylate membrane continuous hemodiafiltration 60, 61
Acute kidney injury blood purification therapy for acute renal failure anticoagulation low-molecular-weight heparin 124 nafamostat mesilate 124 unfractionated heparin 122–124 indications 120 modes 120–122 cardiovascular surgery cardiopulmonary bypass risk factors 33, 34 continuous hemodialysis findings initiation and patient characteristics 35–37 survival curves 37, 38 pathogenesis 21, 32 postoperative events 34 predictive factors 32, 33 continuous renal replacement therapy modality selection 168–170 diagnostic criteria 41 online continuous hemodiafiltration 174–178 sepsis blood purification therapy continuous versus intermittent therapy 43 dialysis dose 43, 44 initiation timing 43 overview 42, 43 pathophysiology 41, 42 Acute liver failure, see Fulminant hepatic failure Acute pancreatitis, see Severe acute pancreatitis Acute respiratory distress syndrome pathophysiology 84 polymethacrylate membrane continuous hemodiafiltration cytokine levels 86–88 respiratory index changes 86–88 study design 84–86, 90 survival 88, 89 Albumin, loss with super high-flux hemofiltration 185 Anticoagulation, see Low-molecular-weight heparin, Nafamostat mesilate, Unfractionated heparin Artificial liver, fulminant hepatic failure management 68 Burn patients, continuous renal replacement therapy modality selection 169 Cardiopulmonary bypass, see Acute kidney injury Console system, continuous renal replacement therapy alarms 130

191
Console system, continuous renal replacement therapy (continued)
composition and monitoring
air detector 132
anticoagulant pump system 129, 131
blood detector 132
blood flow rate 127, 128
blood inflow sensor 131, 132
coagulation occlusion 132
fluid flow control system 129
pressure monitoring 131
solution flow rates 128, 129
temperature 132
management 132
safety considerations 127
selection 126, 127
settings 129
CTR-001, features and cytokine removal 138
CYT-860
cytokine removal performance 137
structure 136
Cytokine removal
hypercytokinemia in critical illness and sepsis 24
polymethacrylate membrane
continuous hemodiafiltration,
see Polymethacrylate membrane continuous hemodiafiltration
column types and performance
CTR-001 138
CYT-860 136, 137
Cytosorb 136
Lixelle 137, 138
MPCF-X 139
overview 134, 135
pancreatitis, see Severe acute pancreatitis
sepsis, see Sepsis
Cytosorb, features and cytokine removal 136

Double-filtration plasmapheresis, use in Japan 48–51

Fulminant hepatic failure
blood purification therapy
artificial liver 68
hemodialysis and hemofiltration 66, 67, 69–71
Molecular Adsorbent Recirculating System 68
plasma exchange 67
rationale 65, 66
overview 64, 65

Hemodiafiltration, continuous
advantages over intermittent hemodialysis 159
cytokine removal 24, 25
elimination efficiency 16
fulminant hepatic failure management 66, 67, 69–71
high-volume and high-flow techniques 16, 17
membrane selection 113–115
online technique
acute kidney injury management 174–178
equipment 174
maintenance 175, 177, 178
overview 51, 174
quality control 175, 176
overview 14
pediatric patients
anticoagulation 164
body temperature 164, 165
coagulation within circuit 164
indications 159
priming volume 160–162
problems 160
vascular access 162–164
water imbalance influence on hemodynamics 162
polymethacrylate membrane continuous hemodiafiltration,
see Polymethacrylate membrane continuous hemodiafiltration
principles 106, 107

Hemodialysis, continuous
cardiac patient findings
initiation and patient characteristics 35–37
survival curves 37, 38
conventional hemodialysis 106
elimination efficiency 15
fulminant hepatic failure management 66
high cut-off membranes 186
high-volume and high-flow techniques 16, 17
membrane selection 102, 103
overview 14
Hemofiltration
conventional hemofiltration 106
elimination efficiency 16
high-volume and high-flow techniques 16, 74, 101
membrane selection 102, 103
overview 14
principles 107
super high-flux, see Super high-flux hemofiltration
Hemoperfusion, direct 108, 109
Heparin, see Low-molecular-weight heparin, Nafamostat mesilate, Unfractionated heparin
Hepatoencephalopathy, fulminant hepatic failure 65
High-mobility group box-1 protein, removal with super high-flux/high cut-off membrane 187, 188
Hypercytokinemia, see Cytokine removal
Intensive care
indications for blood purification 21–28, 105
nephrology interactions 2
Interleukin-6, see Cytokine removal, Polymethacrylate membrane continuous hemodiafiltration
Intoxication
blood purification therapy
indications 94, 95
modes 94, 95
Molecular Adsorbent Recirculating System 96
plasma diafiltration 96, 98, 99
plasma exchange 97
protein-bound intoxicants 96
classification of intoxicants 94
Japan, blood purification therapy
classification in critical care
blood drawing and returning 14, 15, 18
hemofilter-based purification
modes 14, 18, 19, 49–51
high-volume and high-flow techniques 16, 17
flow rate expressions 17, 18
indications 5, 47
modes 5–7
outcomes 7–9
survey 5
terminology in critical care 11–14
Liver failure, see Fulminant hepatic failure
Lixelle, features and cytokine removal 137, 138
Low-molecular-weight heparin, anticoagulation for blood purification therapy in acute renal failure 124
Molecular Adsorbent Recirculating System
fulminant hepatic failure management 68
intoxication management 96
MPCF-X, features and cytokine removal 139
Mushroom intoxication, blood purification therapy 97, 98
Nafamostat mesilate, anticoagulation for blood purification therapy in acute renal failure 124
pediatric continuous hemodiafiltration 164
Neutrophil, polymethacrylate membrane continuous hemodiafiltration effects 79
Pancreatitis, see Severe acute pancreatitis
Pediatric patients, see Hemodiafiltration, continuous

Plasma diafiltration
intoxication management 96, 98, 99
principles 108
sepsis management
multicenter study 146, 147
overview 142, 143, 147, 148
single-center study 145
study design 143–145

Plasma exchange
fulminant hepatic failure
management 67
intoxication management 97
principles 107
single- versus double-filtration 107, 108

Plasma perfusion, principles 109

Poisoning, see Intoxication

Polyacrylonitrile membrane,
characteristics 114, 118

Polymethacrylate membrane continuous hemodiafiltration
acute respiratory distress syndrome
management
cytokine levels 86–88
respiratory index changes 86–88
study design 84–86, 90
survival 88, 89
cytokine removal and indications 24, 25, 27, 49, 50, 75
immunomodulatory effects 78–80
membrane characteristics 114–118
sepsis management 25, 26, 74–80
severe acute pancreatitis
abdominal compartment syndrome
benefits 60, 61
initiation and weaning criteria 56–58
interleukin-6 response 59
outcomes 59, 60
overview 61, 62

Polymyxin B direct hemoperfusion
column design 151, 152
hemodynamic response in septic shock 152
limitations 155

Sepsis
acute kidney injury
blood purification therapy
continuous versus intermittent therapy 43
dialysis dose 43, 44
initiation timing 43
overview 42, 43
pathophysiology 41, 42
continuous renal replacement therapy
modality selection 169, 170
plasma diafiltration
multicenter study 146, 147
overview 142, 143, 147, 148
single-center study 145
study design 143–145
polymethacrylate membrane
continuous hemodiafiltration 25, 26, 74–80
polymyxin B direct hemoperfusion 25, 26, 42, 77, 152–156
refractory septic shock
management 80

Severe acute pancreatitis
hypercytokinemia
evaluation 55, 56
overview 55
polymethacrylate membrane
continuous hemodiafiltration
abdominal compartment syndrome
benefits 60, 61
initiation and weaning criteria 56–58
interleukin-6 response 59
outcomes 59, 60
overview 61, 62
Super high-flux hemofiltration
albumin loss and safety issues
185
ex vivo findings 183, 184
high-mobility group box-1 protein
removal 187, 188
membrane features 182, 183
monocyte function effects 184, 185
pilot clinical study 184

Temperature
monitoring in continuous renal
replacement therapy 132
pediatric body temperature
monitoring 164, 165

Unfractionated heparin, anticoagulation
for blood purification therapy in acute
renal failure 122–124